| KAI Pharma enters agreement with Ono Pharma for development of KAI-4169 in Japan - pharmabiz.com |
|
|
pharmabiz.com Phase 1 data have demonstrated that single IV doses of KAI-4169 were safe and well-tolerated and resulted in sustained reductions in serum levels of parathyroid hormone in both healthy male subjects and end-stage renal disease (ESRD) patients with |